Acadia Pharmaceuticals Inc (ACAD) income statement
ACADNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3027% below fair value
$17.83−0.49 (-2.67%)
Close on Nov 18, 2026Market cap $3.07BP/E 8.1Yield –
Acadia Pharmaceuticals Inc income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 91.1%
- Operating margin
- 7.6%
- Net margin
- 33.4%
- Return on equity, FY2025
- 39.9%
Financial strength
- Current ratio
- 3.39
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 106.5%
Valuation
- P/E ratio
- 8.1
- Price to sales
- 2.70
- Price to book
- 2.35
- Dividend yield
- –
See a number that looks wrong?